Skip to main content
Equibles
KMDA logo

KMDA · Kamada Ltd

Track KMDA — free

Use KMDA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about KMDA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.38 -0.25 (-2.90%) At close · Aug 26
Market Cap
$497.90M
Shares
57.69M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.38 Open$8.51 Day$8.31–8.64 52W close$6.60–9.31 Avg vol 30d119K Short int150K · 0.3% float · 1.3d Short vol38% Last earningsAug 12, 2026 DataJan 2020–Aug 2026

Up next

Next earnings call
Dec 17, 2026 Est · unconfirmed · in 16 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 15.2 · calm Equity put/call 0.64
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg +14%
above
RSI (14) 68
neutral
MACD trend Positive
52-week position 66%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +20%
trailing
6-month return −7%
trailing
YTD return +19%
this year
Relative strength −20%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+19% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.26% of float · ▲ +14.0% MoM · 1.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
51 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 34%
annualized · 1-yr
Max drawdown −26%
past year
ATR 2.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Mar 31, 2026
2026 annual
Revenues $200M – $205M
Adjusted EBITDA Non-GAAP $50M – $53M
within the next four to five years
Biosimilars annual sales $15M – $20M
at full capacity
Annual revenues in sales of normal source plasma $8M – $10M
Prior guidance period ended · from the Earnings Call filed Sep 30, 2025
Annual revenue · 2025 $178M – $182M
Adjusted EBITDA · 2025 $40M – $44M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
+14% Bullish
RSI (14)
68 Neutral
MACD trend
Positive Bullish
52-week position
66% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+19% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.26% of float · ▲ +14.0% MoM · 1.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
51 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $8 · 66% Range high $9
vs 200-day avg +8% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KMDA
Kamada Ltd
this stock
$497.90M +18.7% — — 0.3%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $58.22B +16.9% — — 0.1%
GALDY
Galderma Group AG/ADR
 $49.94B +2.3% — — 0.0%
HLN
Haleon plc
 $44.77B +0.6% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
51
% held
8.6%
Net QoQ
-162.3K sh
Top holder
Phoenix Financial Ltd.
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
149.6K
Days to cover
1.3d
Change
+18.4K sh
View
Short Volume
Short vol %
38%
As of
Aug 26, 2026
Short Total
View
Fails to Deliver
FTD shares
29
Value
$204
As of
Jul 20, 2026
View
Off-Exchange
Off-exchange %
46.5%
Week of
Jul 20, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 17, 2026
This year
17
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

5D 20D 120D MTD YTD
KMDA +6.2% +19.5% -7.2% +17.4% +18.7%
SPY -0.4% +5.0% +12.4% +2.6% +12.3%
vs SPY +6.6% +14.5% -19.6% +14.8% +6.4%

Capital returns

Latest dividend
$0.17 / share · ex Aug 27, 2026
Cut 32%
Paid (TTM)
$0.42 / share · 2 payouts
Dividend yield (TTM, derived)
— · history filling in

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1567529 CUSIP M6240T109 13F (30d) 48 filings 47 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)